No announcement yet.

CoronaVirus - non political thread


Google Ads

  • Filter
  • Time
  • Show
Clear All
new posts

  • Originally posted by sctrojan View Post
    So recently there was an anti mask/anti vaccine rant in San Diego and the internet never misses a chance to produce greatness

    This kinda slaps tbh


    • From what I understand, the booster is somewhat useful, because further from vaccination you get, the more likely to get a breakthrough....but also somewhat useless, because it's not going to protect much more against variants. What they need is a delta variant vaccine.


      • Moderna Vaccine More Effective Than Pfizer, J&J, Especially After 4 Months: CDC


        • Does My Mask Protect Me if Nobody Else Is Wearing One?

          By Tara Parker-Pope
          September 21, 2021 Original article
          Stay 'in the know' with a look at popular health news patients are reading.

          If I’m the only person wearing a mask in a store or other indoor location, am I really protected from infection?

          It’s true that masks work best when everyone in the room is wearing one. That’s because when an infected person wears a mask, a large percentage of their exhaled infectious particles are trapped, stopping viral spread at the source. And when fewer viral particles are floating around the room, the masks others are wearing would likely block those that have escaped.

          But there is also plenty of evidence showing that masks protect the wearer even when others around them are mask-free. The amount of protection depends on the quality of the mask and how well it fits. During a hotel outbreak in Switzerland, for instance, several employees and a guest who tested positive for the coronavirus were wearing only face shields (with no masks); those who wore masks were not infected. And a Tennessee study found that communities with mask mandates had lower hospitalization rates than areas where masks weren’t required.

          “Health care workers, scientists who work with nasty pathogens, and workers who may be exposed to hazardous airborne particles on the job rely on specialized masks like N95s for protection, so we know that properly fitted, high-efficiency masks work,” said Linsey Marr, a Virginia Tech engineering professor and one of the world’s leading experts on viral transmission.

          A number of laboratory studies have also documented that a mask protects the person who is wearing it, though the level of that protection can vary depending on the type of mask, the material it’s made from, the experimental setup and how particle exposure was measured.

          But the bottom line of all the studies is that a mask reduces the potential exposure of the person wearing it. Here are some of the findings.
          • One study from the Centers for Disease Control and Prevention found that a standard surgical mask only protected the wearer from about 7.5 percent of the particles generated by a simulated cough. But knotting the loops and tucking in the sides of the medical mask reduced exposure by nearly 65 percent. (Watch this video to see the “knot and tuck” method.) Covering the surgical mask with a cloth mask, a technique known as double masking, reduced exposure to the simulated cough particles by 83 percent.
          • A Virginia Tech study looked at how well homemade masks, surgical masks and face shields protected the wearer, based on particle size. The research showed that most masks could block very large particles, like those from a sneeze. But when the researchers looked at smaller aerosol particles that are hardest to block, protection ranged from near zero with a face shield to about 30 percent protection with a surgical mask. (The percentages in the study can’t be directly compared to the C.D.C. knot-and-tuck study because the testing methods were different.) Based on the findings, Dr. Marr and her colleagues concluded that a two-layer cloth mask made of flexible, tightly-woven fabric, combined with a filter material (like a coffee filter or surgical mask), could offer good protection, reducing 70 percent of the most penetrating particles and trapping 90 percent or more of the larger particles. They also found that head straps or ties created a better fit than ear loops.
          • A study from Tokyo tested how well different types of masks protected the wearer from actual coronavirus particles. The study showed that even a simple cotton mask offered some protection (17 to 27 percent) to the wearer. Medical masks performed better, including a surgical mask (47 to 50 percent protection), a loose fitting N95 (57 to 86 percent protection) and a tightly sealed N95 (79 to 90 percent protection).
          • While many lab studies test masks using mannequin heads, a 2008 study used real people to measure how well masks could protect the wearer against a respiratory virus. The study subjects wore different kinds of masks fitted with special receptors that could measure particle concentration on both sides of the masks. In this study, cloth masks reduced exposure by 60 percent, surgical masks by 76 percent and N95 masks by 99 percent.

          While the lab studies all show a mask can protect the wearer, how well the masks perform in the real world depends on a number of variables, including how consistently people use them, whether a person is in high-risk situations and the rate of infection in the community. A Danish study of 6,000 participants, half of whom were told to wear masks, didn’t show a benefit to mask wearing, but the study has been widely criticized for its poor design.

          The laboratory studies showed that a high-quality medical mask, like an N95, KN95 or KF94, works best. While vaccination is the best protection against Covid-19, even vaccinated people are advised to avoid crowds or large groups indoors when the vaccination status of others isn’t known. Given that the Delta variant is far more contagious than other variants, Dr. Marr also recommended wearing the highest-quality mask possible when you can’t keep your distance or be outdoors — or when nobody around you is masking up.

          “If I’m in a situation where I have to rely solely on my mask for protection — unvaccinated people may be present, it’s crowded, I don’t know anything about the ventilation — I would wear the best mask in my wardrobe, which is an N95,” said Dr. Marr. “Because Delta has proved to be so much more easily transmitted and because vaccinated people can transmit, we need to wear the best masks possible in high-risk situations.”

          Tara Parker-Pope is a columnist covering health, behavior and relationships. She is the founding editor of Well, The Times's award-winning consumer health site. @taraparkerpopeFacebook

          This article first appeared on The New York Times and was republished with permission. Copyright: c.2021 The New York Times Company




            • I'd love to staple this report on the foreheads of DeSantis, Abbott and Noem


              • Top Questions Answered About COVID Boosters for Your Patients

                Damian McNamara

                September 24, 2021

                Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

                Confusion continues to circulate in the wake of decisions on booster doses of the Pfizer/BioNTech COVID-19 vaccine, all announced within 1 week. Many people — including those now eligible and those who officially have to wait for their shot at a third dose — have questions.

                Multiple agencies are involved in the booster decisions, and they have put out multiple — and sometimes conflicting — messages about booster doses, leaving more questions than answers for many people.

                On September 22, the US Food and Drug Administration (FDA) granted an emergency use authorization (EUA) for a booster dose of the Pfizer mRNA COVID vaccine for those 65 and older and those at high risk for severe illness from the coronavirus, including essential workers whose jobs increase their risk for infection — such as frontline healthcare workers.

                Early this morning, the Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky, MD, overruled advice from the agency's Advisory Committee on Immunization Practices (ACIP) to recommend boosters for essential workers such as those working on the frontlines during the pandemic.

                As it stands now, the CDC recommends that the following groups should get a third dose of the Pfizer vaccine:
                • People aged 65 years and older
                • People aged 18 years and older in long-term care settings
                • People aged 50 - 64 years with underlying medical conditions

                The CDC also recommends that the following groups may receive a booster shot of the Pfizer vaccine, based on their individual benefits and risks:
                • People aged 18 - 49 years with underlying medical conditions
                • People aged 18 - 64 years at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting

                The CDC currently considers the following groups at increased risk for COVID-19:
                • First responders (healthcare workers, firefighters, police, congregate care staff)
                • Education staff (teachers, support staff, day care workers)
                • Food and agriculture workers
                • Manufacturing workers
                • Corrections workers
                • US postal service workers
                • Public transit workers
                • Grocery store workers

                Healthcare professionals, among the most trusted sources of COVID-19 information, are likely to encounter a number of patients wondering how all this will work.

                "It's fantastic that boosters will be available for those who the data supports need [them]," Rachael Piltch-Loeb, PhD, said during a media briefing on September 23, held between the FDA and CDC decisions.

                "But we're really in a place where we have a lot more questions and answers about what the next phase of the vaccine availability and updates are going to be in the United States," added Piltch-Loeb, preparedness fellow in the Division of Policy Translation and Leadership Development and a research associate in the Department of Biostatistics at the Harvard T H Chan School of Public Health in Boston, Massachusetts.

                To provide some initial answers, Medscape Medical News spoke with multiple COVID-19 experts.
                1. What is the biggest concern you are hearing from patients about getting a booster?

                "The biggest concerns are that everyone wants it and they don’t know where to get it. In healthcare’s defense, the CDC just figured out what to do this morning," said Janet Englund, MD, professor of pediatric infectious diseases and an infectious disease and virology expert at Seattle Children’s Hospital in Washington.

                "Everyone thinks they should be eligible for a booster…people in their 50s who are not yet 65+, people with young grandchildren, etc.," she added. "I’m at Seattle Children's Hospital, so people are asking about booster shots and about getting their children vaccinated."

                Boosters for all COVID-19 vaccines are completely free.

                "All COVID-19 vaccines, including booster doses, will be provided free of charge to the US population," the CDC said Thursday.
                2. Will patients need to prove they meet eligibility criteria for a booster shot or will it be the honor system?

                "No, patients will only need to attest that they fall into one of the high-risk groups for whom a booster vaccine is authorized," said Robert Atmar, MD, professor of infectious diseases at Baylor College of Medicine in Houston, Texas.

                Piltch-Loeb agreed. "it is likely to be an honor system. It is very unlikely that there will be punishments or other ramifications…if doses are administered, beyond the approved usage."
                3. If a patient who had the Moderna or the Johnson and Johnson vaccination requests a booster, can healthcare workers give them Pfizer?

                The short answer is no. "This only applies to individuals who have received the Pfizer vaccine," Piltch-Loeb said.

                More data will be needed before other vaccine boosters are authorized, she added.

                "My understanding is the Moderna people have just recently submitted their information, all of their data to the FDA and J&J is in line to do that very shortly," said William Schaffner, MD, a professor of preventive medicine and infectious diseases at Vanderbilt University in Nashville, Tennessee.

                "I would hope that within the next month to six weeks, we will get information about both of those vaccines," Schaffner said.
                4. When are the "mix-and-match" vaccine study results expected to come out?

                "We expect that data from the study will be available in the coming weeks," said Atmar, who is also national coprincipal investigator of a mix-and-match booster trial launched in June 2021.
                5. Are side effects of a booster vaccine expected to be about the same as what people experienced during their first or second immunization?

                "I’m expecting the side effects will be similar to the second dose," Englund said.

                "The data presented yesterday at ACIP suggests that the side effects from the third shot are either the same or actually less than the first two shots," said Carlos del Rio, MD, distinguished professor of medicine, epidemiology and global health and executive associate dean of Emory University School of Medicine at Grady Health System in Atlanta, Georgia.

                ”Everyone reacts very differently to vaccines, regardless of vaccine type," said Eric Ascher, MD, a family medicine physician at Lenox Hill Hospital in New York City. "I have had patients (as well as personal experience) where there were none to minimal symptoms, and others who felt they had a mild flu for 24 hours."

                "I expect no side effects greater than what was felt with you prior doses," he said. "The vaccine is very safe and the benefit of vaccination outweighs the risks of any mild side effects."
                6. Is it unethical to give a booster to someone outside the approved groups if there are doses remaining at the end of the day in an open vial?

                "Offering a booster shot to someone outside of approved groups if remaining doses will go to waste at the end of the day seems like a prudent decision, and relatively harmless action," said Faith Fletcher, PhD, assistant professor at the Center for Medical Ethics and Health Policy at Baylor College of Medicine.

                "However, if doses continue to fall in the laps of unapproved groups, we must evaluate the vaccine systems and structures that advantage some groups and disadvantage others," she added. "We know that the distribution of Covid-19 vaccines has not been equitable — and some groups have been left behind."

                "I am not an ethicist and there are many competing concerns that this question addresses," Atmar said. For example, "there is not a limitation of vaccine supply in the US, so that using left-over vaccine to prevent waste is no longer a major concern in the US."

                It could be more of a legal than ethical question, Atmar said. For an individual outside the authorized groups, legally, the FDA's EUA for boosting does not allow the vaccine to be administered to this person, he said.

                "The rationale for the restricted use in the EUA is that at this time the safety and risks associated with such administration are not known, and the benefits also have not been determined," Atmar said. "Members of the ACIP raised concerns about other individuals who may potentially benefit from a booster but are not eligible and the importance of making boosters available to them, but from a legal standpoint — I am also not a lawyer, so this is my understanding — administration of the vaccine is limited to those identified in the EUA."
                7. What is the likelihood that one shot will combine COVID and flu protection in the near future?

                It is not likely, Englund said. "The reason is that the flu vaccine changes so much, and it already has four different antigens. This is assuming we keep the same method of making the flu vaccine — the answer could be different if the flu vaccine becomes an mRNA vaccine in the future."

                Companies such as Moderna and Novavax are testing single-dose shots for COVID and influenza, but they are still far from having anything ready for this flu season in the United States.
                8. Is there any chance a booster shot distributed now will need to be redesigned for a future variant?

                "Absolutely," Englund said. "And a booster dose is the time we may want to consider re-engineering a vaccine."
                9. Do you think the FDA/CDC limitations on who is eligible for a booster was in any way influenced by the World Health Organization call for prioritizing shots for the unvaccinated in lower-resource countries?

                "This is absolutely still a global problem," Piltch-Loeb said. "We need to get more of vaccine to more countries and more people as soon as possible, because if there's anything we've seen about the variants it is that…they can come from all different places."

                "That being said, I think that it is unlikely to change the course of action in the US," she added, when it comes to comparing the global need with the domestic policy priorities of the administration.

                Atmar was more direct. "No," he said. "The WHO recommends against boosting of anyone. The US decisions about boosting those in this country who are eligible are aimed toward addressing perceived needs domestically at the same time that vaccines are being provided to other countries."

                "The philosophy is to address both 'needs' at the same time," Atmar said.
                10. What does the future hold for booster shots?

                "Predicting the future is really hard, especially when it involves COVID," del Rio said.

                "Having said that, COVID is not the flu, so I doubt there will be need for annual boosters. I think the population eligible for boosters will be expanded…and the major population not addressed at this point is the people that received either Moderna or J&J [vaccines]."

                Kelly Davis contributed to this feature.

                Damian McNamara is a staff journalist based in Miami. He covers a wide range of medical specialties, including infectious diseases, gastroenterology, and critical care. Follow Damian on Twitter: @MedReporter.

                For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn.


                Lead Image: iStock/Getty Images

                Medscape Medical News © 2021
                CDC Director Expands Boosters, Urges Unvaccinated to Get Shots

                Lindsay Kalter

                September 24, 2021

                Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

                CDC Director Rochelle Walensky, MD, late Thursday overruled her agency's advisory panel to make boosters available to front-line workers. But unless the unvaccinated get their shots, the extra protection will not be enough, she said at a Friday briefing.

                The CDC's Advisory Committee on Immunization Practices on Thursday recommended the boosters for all people 65 and older and for those 50 to 64 who have medical conditions.

                Though the committee voted against broadening the recommendation for people 18 to 64 who are at higher risk because of their occupations, Walensky overrode that decision. Those include front-line workers like health care staff, grocery store employees, and teachers.

                "Had I been in the room and on the committee, I would have voted yes," she said. "That is reflected in my resulting decision to allow the use of the Pfizer-BioNTech COVID-19 booster dose for those 18 and older at high risk of COVID-19 exposure and transmission because of occupational and institutional exposure."

                But that will not be enough to beat the virus, Walensky said.

                "I want to be clear: We will not boost our way out of this pandemic," she said. "Infections among the unvaccinated continue to fuel this pandemic, resulting in a rising number of cases, hospitalizations, and deaths."

                About 60 million Americas will be eligible for a third dose of the vaccine after 6 months, and 20 million are already eligible, federal health officials said.

                "We are ready to get booster shots in arms right away," said White House COVID-19 Response Coordinator Jeff Zients. "We've secured enough boosters for every American," which, he said, will be free for everyone regardless of immigration or insurance status.

                President Joe Biden said during a Friday morning briefing that booster shots are available starting today in more than 80,000 locations nationwide, including 40,000 pharmacies.

                As of now, only those who received the Pfizer vaccine are eligible for a third shot. That is likely to change in the coming weeks, said U.S. Surgeon General Vivek H. Murthy, MD.

                Murthy, speaking directly to Moderna and Johnson & Johnson vaccine recipients, said getting boosters approved for everyone is a "high, high priority."

                "Your health matters just as much as other vaccine recipients," he said. "We want to make sure your protection against COVID-19 is strong and reliable as well. That's why the FDA is working closely with Moderna and J&J to get and process their data as quickly as possible.

                Top infectious disease expert Anthony Fauci, MD, warned the public that getting boosters before the 6-month period is up will lessen their effectiveness.

                "If you allow the immune response to mature over a period of a few months, you get much more of a bang out of the shot," he said. "There might be a natural feeling of, 'Well gee, I'm getting anxious, I really want to get my third shot right now.'…You want to make sure there's an immunological reason for that time frame."


                News briefing, White House COVID-19 Response Team, Sept. 24, 2021.

                News briefing, President Joe Biden, Sept. 24, 2021.

                Lead Image: Greg Nash, Pool/Getty Images

                WebMD Health News © 2021
                A Daily Pill to Treat COVID Could Be Just Months Away, Scientists Say

                JoNel Aleccia

                September 24, 2021

                Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

                Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.

                When her husband, Joe, 46, fell ill with the virus, too, she really got worried, especially about their five teenagers at home: "I thought, 'I hope to God we don't wind up on ventilators. We have children. Who's going to raise these kids?"

                But the Kellys, who live in Seattle, had agreed just after their diagnoses to join a clinical trial at the nearby Fred Hutch cancer research center that's part of an international effort to test an antiviral treatment that could halt covid early in its course.

                By the next day, the couple were taking four pills, twice a day. Though they weren't told whether they had received an active medication or placebo, within a week, they said, their symptoms were better. Within two weeks, they had recovered.

                "I don't know if we got the treatment, but I kind of feel like we did," Miranda Kelly said. "To have all these underlying conditions, I felt like the recovery was very quick."

                The Kellys have a role in developing what could be the world's next chance to thwart covid: a short-term regimen of daily pills that can fight the virus early after diagnosis and conceivably prevent symptoms from developing after exposure.

                "Oral antivirals have the potential to not only curtail the duration of one's covid-19 syndrome, but also have the potential to limit transmission to people in your household if you are sick," said Timothy Sheahan, a virologist at the University of North Carolina-Chapel Hill who has helped pioneer these therapies.

                Antivirals are already essential treatments for other viral infections, including hepatitis C and HIV. One of the best known is Tamiflu, the widely prescribed pill that can shorten the duration of influenza and reduce the risk of hospitalization if given quickly.

                The medications, developed to treat and prevent viral infections in people and animals, work differently depending on the type. But they can be engineered to boost the immune system to fight infection, block receptors so viruses can't enter healthy cells, or lower the amount of active virus in the body.

                At least three promising antivirals for covid are being tested in clinical trials, with results expected as soon as late fall or winter, said Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, who is overseeing antiviral development.

                "I think that we will have answers as to what these pills are capable of within the next several months," Dieffenbach said.

                The top contender is a medication from Merck & Co. and Ridgeback Biotherapeutics called molnupiravir, Dieffenbach said. This is the product being tested in the Kellys' Seattle trial. Two others include a candidate from Pfizer, known as PF-07321332, and AT-527, an antiviral produced by Roche and Atea Pharmaceuticals.

                They work by interfering with the virus's ability to replicate in human cells. In the case of molnupiravir, the enzyme that copies the viral genetic material is forced to make so many mistakes that the virus can't reproduce. That, in turn, reduces the patient's viral load, shortening infection time and preventing the kind of dangerous immune response that can cause serious illness or death.

                So far, only one antiviral drug, remdesivir, has been approved to treat covid. But it is given intravenously to patients ill enough to be hospitalized, and is not intended for early, widespread use. By contrast, the top contenders under study can be packaged as pills.

                Sheahan, who also performed preclinical work on remdesivir, led an early study in mice that showed that molnupiravir could prevent early disease caused by SARS-CoV-2, the virus that causes covid. The formula was discovered at Emory University and later acquired by Ridgeback and Merck.

                Clinical trials have followed, including an early trial of 202 participants last spring that showed that molnupiravir rapidly reduced the levels of infectious virus. Merck chief executive Robert Davis said this month that the company expects data from its larger phase 3 trials in the coming weeks, with the potential to seek emergency use authorization from the Food and Drug Administration "before year-end."

                Pfizer launched a combined phase 2 and 3 trial of its product Sept. 1, and Atea officials said they expect results from phase 2 and phase 3 trials later this year.

                If the results are positive and emergency use is granted for any product, Dieffenbach said, "distribution could begin quickly."

                That would mean millions of Americans soon could have access to a daily orally administered medication, ideally a single pill, that could be taken for five to 10 days at the first confirmation of covid infection.

                "When we get there, that's the idea," said Dr. Daniel Griffin, an infectious diseases and immunology expert at Columbia University. "To have this all around the country, so that people get it the same day they get diagnosed."

                Once sidelined for lack of interest, oral antivirals to treat coronavirus infections are now a subject of fierce competition and funding. In June, the Biden administration announced it had agreed to obtain about 1.7 million treatment courses of Merck's molnupiravir, at a cost of $1.2 billion, if the product receives emergency authorization or full approval. The same month, the administration said it would invest $3.2 billion in the Antiviral Program for Pandemics, which aims to develop antivirals for the covid crisis and beyond, Dieffenbach said.

                The pandemic kick-started a long-neglected effort to develop potent antiviral treatments for coronaviruses, said Sheahan. Though the original SARS virus in 2003 gave scientists a scare — followed by Middle East respiratory syndrome, or MERS, in 2012 — research efforts slowed when those outbreaks did not persist.

                "The commercial drive to develop any products just went down the tubes," said Sheahan.

                Widely available antiviral drugs would join the monoclonal antibody therapies already used to treat and prevent serious illness and hospitalizations caused by covid. The lab-produced monoclonal antibodies, which mimic the body's natural response to infection, were easier to develop but must be given primarily through intravenous infusions.

                The federal government is covering the cost of most monoclonal products at $2,000 a dose. It's still too early to know how the price of antivirals might compare.

                Like the monoclonal antibodies, antiviral pills would be no substitute for vaccination, said Griffin. They would be another tool to fight covid. "It's nice to have another option," he said.

                One challenge in developing antiviral drugs quickly has been recruiting enough participants for the clinical trials, each of which needs to enroll many hundreds of people, said Dr. Elizabeth Duke, a Fred Hutch research associate overseeing its molnupiravir trial.

                Participants must be unvaccinated and enrolled in the trial within five days of a positive covid test. Any given day, interns make 100 calls to newly covid-positive people in the Seattle area — and most say no.

                "Just generally speaking, there's a lot of mistrust about the scientific process," Duke said. "And some of the people are saying kind of nasty things to the interns."

                If the antiviral pills prove effective, the next challenge will be ramping up a distribution system that can rush them to people as soon as they test positive. Griffin said it will take something akin to the program set up last year by UnitedHealthcare, which sped Tamiflu kits to 200,000 at-risk patients enrolled in the insurer's Medicare Advantage plans.

                Merck officials predicted the company could produce more than 10 million courses of therapy by the end of the year. Atea and Pfizer have not released similar estimates.

                Even more promising? Studies evaluating whether antivirals can prevent infection after exposure.

                "Think about that," said Duke, who is also overseeing a prophylactic trial. "You could give it to everyone in a household, or everyone in a school. Then we're talking about a return to, maybe, normal life."


                Lead Image: Merck

                Kaiser Health News © 2021


                • How Ivermectin Became The New Focus Of The Anti-Vaccine Movement

                  Dying after leaving AMA


                  • Dozens Of Massachusetts State Police Have Resigned Over A Vaccine Mandate, Union Says

                    Good riddance of retards



                      Harvard Business School says it is reverting to remote learning after beginning the semester with in-person classes, citing a rise in breakthrough COVID-19 cases among its students.

                      The move comes after "a steady rise in breakthrough infections" among the business school's student population.
                      Interesting.... so it must be because of all those unvaccinated people running around....

                      Ninety-six percent of Harvard University's employees are vaccinated, while 95% of its students are vaccinated, according to the university's COVID-19 testing dashboard.

                      Damn unvaccinated folks.


                      • Originally posted by ibleed View Post


                        Interesting.... so it must be because of all those unvaccinated people running around....

                        Damn unvaccinated folks.

                        You tried. It's the unvaccinated clogging up the ICU's and taking beds away from people needing things like Cancer treatment. But you already knew that.

                        Also, from your article.

                        "Contact tracers who have worked with positive cases highlight that transmission is not occurring in classrooms or other academic settings on campus. Nor is it occurring among individuals who are masked," Cautela added.

                        Why did you leave put that masks are working?


                        • Originally posted by BChris View Post

                          You tried. It's the unvaccinated clogging up the ICU's and taking beds away from people needing things like Cancer treatment. But you already knew that.

                          Also, from your article.

                          "Contact tracers who have worked with positive cases highlight that transmission is not occurring in classrooms or other academic settings on campus. Nor is it occurring among individuals who are masked," Cautela added.

                          Why did you leave put that masks are working?
                          None of what you said addresses the fact that an almost fully vaccimated population is still catching and spreading the virus, despite being told that all we has to do is get vaccinated and we can go back to normal amd take off the mask.


                          • Originally posted by ibleed View Post

                            None of what you said addresses the fact that an almost fully vaccimated population is still catching and spreading the virus, despite being told that all we has to do is get vaccinated and we can go back to normal amd take off the mask.
                            I don't follow blogs, but I know I've heard time and time again that getting the vaccine won't stop you from getting it, just keep you from getting so sick you don't end up on a ventilator. And a lot of that "get the vaccine and go back to normal stuff" probably hasn't happened because there are a bunch of retards running around who won't get it because they believe some of the dumbest shit on earth. See previous posts about ICU's filling up and who they are for reference.


                            • Originally posted by ibleed View Post

                              None of what you said addresses the fact that an almost fully vaccimated population is still catching and spreading the virus, despite being told that all we has to do is get vaccinated and we can go back to normal amd take off the mask.

                              Vaccinated people spread the virus at a lesser rate than unvaccinated people. Vaccinated people who get COVID are far less likely to become hospitalized and clog up the ICU than unvaccinated people. The second is the biggest reason some areas can’t go back to normal.


                              • Originally posted by BChris View Post

                                I don't follow blogs, but I know I've heard time and time again that getting the vaccine won't stop you from getting it, just keep you from getting so sick you don't end up on a ventilator. And a lot of that "get the vaccine and go back to normal stuff" probably hasn't happened because there are a bunch of retards running around who won't get it because they believe some of the dumbest shit on earth. See previous posts about ICU's filling up and who they are for reference.
                                Really quick: for context lest there be confusiom on where I stamd- I really don't care about anyone's vaccination status. I'm not going to tell anyone to NOT get it. I'm also not going to demand anybody be fired/shamed/discriminated against if they don't get it. I think older folks and those with health issies shpuld get it. The rest can decide for themselves and I won't judge one way or the other.

                                That said....

                                For months, we've been getting told to just get it and you can go back to normal....but that's not what is happening. No matter what vaccine milestone gets hit, "back to normal" never happens...something ELSE has to happen first. It's always something ELSE.

                                The question that many people are asking now is "If I have to do everything I've been doing BEFORE getting vaccinated AFTER getting vaccinated...what's the point?"

                                I think that's a perfectly valid question.